A 26-Week, Multicenter, Randomized, Placebo-Controlled,
Double-Blind, Parallel Group, Phase 3 Trial with a 26-Week Safety
Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5
and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with
Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years
of Age
Please contact us for more information or to learn if you are eligible to participate.
